

## LISTING OF CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-40. (Cancelled)

41. (Previously Presented) A method for preventing infection of target cells by human immunodeficiency virus (HIV) type 1 comprising exposing said target cells to an anti-CD4 antibody and a polypeptide that inhibits gp41 activity, wherein the administration of the antibody and the polypeptide have a synergistic effect on the inhibition of HIV infection.
42. (Previously Presented) The method of claim 41, wherein the polypeptide that inhibits gp41 activity is 30 to 50 amino acids in length.
43. (Previously Presented) The method of claim 41, wherein the polypeptide is pentafuside.
44. (Previously Presented) The method of claim 41, wherein the antibody and the inhibitor are administered to a patient at risk for AIDS.
45. (Previously Presented) The method of claim 41, wherein the antibody and the inhibitor are administered to a patient suffering from AIDS.
46. (Previously Presented) The method of claim 41, wherein the antibody and the polypeptide are administered within 8 hours of each other.
47. (New) The method of claim 41, wherein the antibody is administered at a dose of 1 to 50 milligrams per kilogram of body weight.
48. (Previously Presented) The method of claim 41, wherein the antibody is administered at a dose of 5 to 30 milligrams per kilogram of body weight.

49. (Previously Presented) The method of claim 41, wherein the polypeptide is administered at a dose of 0.1 to 10 milligrams per kilogram of body weight.
50. (Previously Presented) The method of claim 41, wherein the polypeptide is administered at a dose of 0.5 to 5 milligrams per kilogram of body weight.
51. (Previously Presented) The method of claim 41, further comprising exposing the target cells to a drug that is a nucleoside reverse transcriptase inhibitor.
52. (Previously Presented) The method of claim 41, wherein the ability of the antibody and the polypeptide to synergistically inhibit HIV-1 infection is determined by a cell-based assay, wherein the cells are peripheral blood mononuclear cells (PBMC), and HIV-1 P24 antigen is measured to determine level of HIV infection.
53. (Previously Presented) The method of claim 52, wherein the HIV-1 assayed is selected from one of the following strains: HIV-1 302076, HIV-1 302077, HIV-1 302143, HIV-1 2054, HIV-1 301714, or HTLV-IIIB.
54. (New) The method of claim 41, wherein the anti-CD4 antibody is the antibody produced by the hybridoma designated 5A8.